Additional file 3: of Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
| Autor: | Taylor, Peter, Saurigny, Didier, Jiri Vencovsky, Takeuchi, Tsutomu, Nakamura, Tadashi, Matsievskaia, Galina, Hunt, Barbara, Wagner, Thomas, Souberbielle, Bernard |
|---|---|
| Rok vydání: | 2019 |
| DOI: | 10.6084/m9.figshare.10034597.v1 |
| Popis: | Figure S3. Data are shown for the full set analysis of outcomes for the ACR categorical responses at week 12. (DOCX 20 kb) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|